Department of Internal Medicine IV, University of Heidelberg Hospital, Im Neuenheimer Feld 410,69120 Heidelberg, Germany.
Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg,Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
Biomolecules. 2020 Sep 17;10(9):1332. doi: 10.3390/biom10091332.
Polymorphisms of group VIA calcium-independent phospholipase A2 (iPLA2β orPLA2G6) are positively associated with adiposity, blood lipids, and Type-2 diabetes. Theubiquitously expressed iPLA2β catalyzes the hydrolysis of phospholipids (PLs) to generate a fattyacid and a lysoPL. We studied the role of iPLA2β on PL metabolism in non-alcoholic fatty liverdisease (NAFLD). By using global deletion iPLA2β-null mice, we investigated three NAFLD mousemodels; genetic Ob/Ob and long-term high-fat-diet (HFD) feeding (representing obese NAFLD) aswell as feeding with methionine- and choline-deficient (MCD) diet (representing non-obeseNAFLD). A decrease of hepatic PLs containing monounsaturated- and polyunsaturated fatty acidsand a decrease of the ratio between PLs and cholesterol esters were observed in all three NAFLDmodels. iPLA2β deficiency rescued these decreases in obese, but not in non-obese, NAFLD models.iPLA2β deficiency elicited protection against fatty liver and obesity in the order of Ob/Ob › HFD »MCD. Liver inflammation was not protected in HFD NAFLD, and that liver fibrosis was evenexaggerated in non-obese MCD model. Thus, the rescue of hepatic PL remodeling defect observedin iPLA2β-null mice was critical for the protection against NAFLD and obesity. However, iPLA2βdeletion in specific cell types such as macrophages may render liver inflammation and fibrosis,independent of steatosis protection.
VIA 组钙非依赖性磷脂酶 A2(iPLA2β 或 PLA2G6)的多态性与肥胖、血脂和 2 型糖尿病呈正相关。广泛表达的 iPLA2β 催化磷脂(PL)水解生成脂肪酸和溶血 PL。我们研究了 iPLA2β 在非酒精性脂肪性肝病(NAFLD)中对 PL 代谢的作用。通过使用全局缺失 iPLA2β 基因敲除小鼠,我们研究了三种 NAFLD 小鼠模型;遗传肥胖 Ob/Ob 和长期高脂肪饮食(代表肥胖型 NAFLD)以及蛋氨酸和胆碱缺乏饮食(代表非肥胖型 NAFLD)。在所有三种 NAFLD 模型中,肝 PL 中含有单不饱和和多不饱和脂肪酸的含量以及 PL 与胆固醇酯的比例均降低。iPLA2β 缺乏症可挽救肥胖型而非非肥胖型 NAFLD 模型中的这些减少。iPLA2β 缺乏症按 Ob/Ob > HFD > MCD 的顺序对脂肪肝和肥胖具有保护作用。HFD 诱导的 NAFLD 模型中,肝炎症未得到保护,而非肥胖型 MCD 模型中肝纤维化甚至加剧。因此,iPLA2β 基因敲除小鼠中观察到的肝 PL 重塑缺陷的挽救对于预防 NAFLD 和肥胖至关重要。然而,巨噬细胞等特定细胞类型中 iPLA2β 的缺失可能导致肝炎症和纤维化,而与脂肪变性的保护无关。